Validation of multiparametric MRI with histopathology for prostate cancer

Validation of multiparametric MRI with histopathology for prostate cancer - Validation of multiparametric MRI of prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON40322

Enrollment

Registered

2014-02-03

Start date

2014-01-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

histopathology MRI prostate cancer

Interventions

diagnostic MRI exam will be repeated

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with biopsy-proven prostate cancer who are scheduled for a prostatectomy

Exclusion criteria

Exclusion criteria: • Contra-indications for a MRI exam according to the standard protocol for the screening of patients with prostate cancer • Treatment of prostate cancer prior to the MRI exams • Prior hormonal therapy • Prior trans-urethral resection (TURP) • GFR

Design outcomes

Primary

Measure	Time frame
The robustness of multiparametric imaging for planning of dose painting radiotherapy of prostate cancer is investigated. The variation in the prediction of tumor probability is determined in a test-retest setting.	—

Secondary

Measure	Time frame
• Determine the reproducibility of multi-parametric quantitative MRI • Determine whether there are differences in reproducibility of multi-parametric quantitative MRI between centers • Determine the impact of variations in predicted tumor probability on the planned treatment dose • Validate the predicted tumor probability with whole-mount section histology of prostatectomy specimen	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)